Financial StabilityScholar Rock's balance sheet is strong with $295M cash, $60M in warrants, and $50M debt capacity, sufficient to bridge into approval even under a Class II review.
Market PositionSRRK is seen as one of the most appealing launch stories based on positive channel feedback, flexible regulatory/reimbursement, and an experienced rare disease commercialization team.
Regulatory ProgressDiscussions with the FDA about the BLA have been constructive, indicating a potential for resolution.